EP 3796781 A4 20220420 - BACTERIOPHAGE COMPOSITIONS AND KITS AND RELATED METHODS
Title (en)
BACTERIOPHAGE COMPOSITIONS AND KITS AND RELATED METHODS
Title (de)
BAKTERIOPHAGENZUSAMMENSETZUNGEN SOWIE KITS UND VERWANDTE VERFAHREN
Title (fr)
COMPOSITIONS DE BACTÉRIOPHAGES ET KITS ET PROCÉDÉS ASSOCIÉS
Publication
Application
Priority
- US 201862675652 P 20180523
- US 2019033844 W 20190523
Abstract (en)
[origin: WO2019226950A1] Compositions for affecting the intestinal microbiome of a mammalian subject can include a pharmaceutically-acceptable carrier and greater than or equal to 1x104 PFU/mL or PFU/mg of bacteriophage having a tropism that includes an obesogenic and/or inflammatory bacterium associated with an intestinal microbiome of a mammal. Processes for preparing the disclosed compositions can include isolating the bacteriophage from an environmental source, characterizing the bacteriophage, and combining the bacteriophage with the pharmaceutically acceptable carrier at greater than or equal to1x104 PFU/mL or PFU/mg. Methods can include administering the disclosed compositions to a mammalian subject with or without co-administration of the disclosed probiotics. Administering the disclosed compositions can reduce a concentration of obesogenic and/or inflammatory bacteria in the intestinal microbiome of the mammalian subject, promote or induce weight loss, reduce inflammation, support metabolic health, and/or support a healthy balance/diversity within the intestinal microbiome of the mammalian subject.
IPC 8 full level
A01N 63/50 (2020.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 35/74 (2015.01); A61K 35/741 (2015.01); A61K 35/742 (2015.01); A61K 35/76 (2015.01)
CPC (source: EP US)
A01N 63/50 (2020.01 - EP US); A61K 35/741 (2013.01 - EP US); A61K 35/76 (2013.01 - EP); A61P 3/04 (2017.12 - EP); A61K 9/0048 (2013.01 - EP); A61K 9/0053 (2013.01 - EP); Y02A 50/30 (2017.12 - EP)
Citation (search report)
- [YP] WO 2019048930 A2 20190314 - UNIV KEIO [JP], et al
- [IP] GOGOKHIA LASHA ET AL: "Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis", CELL HOST & MICROBE, vol. 25, no. 2, 19 February 2019 (2019-02-19), pages 285, XP085602358, ISSN: 1931-3128, DOI: 10.1016/J.CHOM.2019.01.008
- [Y] PARMAR KRUPA M ET AL: "Genomic characterization of key bacteriophages to formulate the potential biocontrol agent to combat enteric pathogenic bacteria", ARCHIVES OF MICROBIOLOGY, SPRINGER BERLIN HEIDELBERG, BERLIN/HEIDELBERG, vol. 200, no. 4, 12 January 2018 (2018-01-12), pages 611 - 622, XP036483187, ISSN: 0302-8933, [retrieved on 20180112], DOI: 10.1007/S00203-017-1471-1
- See references of WO 2019226950A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2019226950 A1 20191128; CA 3101242 A1 20191128; CN 112469426 A 20210309; EP 3796781 A1 20210331; EP 3796781 A4 20220420
DOCDB simple family (application)
US 2019033844 W 20190523; CA 3101242 A 20190523; CN 201980049432 A 20190523; EP 19806872 A 20190523